Dapiprazole

Dapiprazole: Overview

Dapiprazole is a synthetic alpha-1 adrenergic receptor antagonist belonging to the phenylpiperazine chemical class used as an ophthalmic miotic agent. It is administered topically as a sterile ophthalmic solution under brand names like Rev-Eyes to reverse iatrogenically induced mydriasis produced by adrenergic or parasympatholytic diagnostic agents, restore pupil light responsiveness, and accelerate recovery of accommodation following routine diagnostic eye examinations.

What Is Dapiprazole & How Does It Work?

Dapiprazole, chemically 3-(2-(4-(2-methylphenyl)piperazin-1-yl)ethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyridine, is a synthetic phenylpiperazine alpha-adrenergic antagonist. Diagnostic mydriatics like phenylephrine stimulate alpha-1 receptors on the iris dilator, while tropicamide blocks cholinergic receptors on the iris sphincter, causing pupillary dilation.

Dapiprazole works through alpha-1 adrenergic receptor blockade, iris dilator relaxation, and pupillary miosis. Following topical instillation, Dapiprazole penetrates corneal membranes into the anterior segment. Inside iris tissue, Dapiprazole competitively blocks alpha-1A, alpha-1B, and alpha-1D adrenergic receptors on smooth muscle cells of the iris dilator muscle. Blocking alpha-1 receptors neutralizes sympathetic tone, causing dilator muscle relaxation. Dilator muscle relaxation permits the iris sphincter to contract, producing rapid miosis and restoring normal light reflexes. Because Dapiprazole acts selectively without ciliary muscle activity, it reverses mydriasis without causing ciliary spasm.

Is Dapiprazole FDA Approved?

Dapiprazole received US FDA approval in December 1990 as a prescription ophthalmic alpha-blocker solution for reversing diagnostic mydriasis.

The FDA approved Dapiprazole hydrochloride under the brand name Rev-Eyes as a powder kit with a diluent vial for ophthalmic reconstitution. The FDA approved Dapiprazole for reversing mydriasis induced by phenylephrine or tropicamide during eye exams. Although commercial distribution of certain formulations has been discontinued in US markets, Dapiprazole remains an approved prescription miotic. Dapiprazole is classified as FDA Approved.

What Is Dapiprazole Used For?

• Reversal of iatrogenically induced mydriasis produced by adrenergic agents like phenylephrine following diagnostic eye exams (FDA Approved).
• Reversal of iatrogenically induced mydriasis produced by parasympatholytic agents like tropicamide following dilated eye exams (FDA Approved).
• Restoration of baseline pupil diameter and light reflex responsiveness (FDA Approved).
• Accelerated recovery of visual acuity and reading ability after pupillary dilation (FDA Approved).
• Management of pigment dispersion syndrome (Off-label use).
• Research evaluating alpha-1 receptor subtype selectivity (Unapproved; research use).

Before Taking Dapiprazole: Contraindications & Precautions

Evaluating ocular surface integrity, anterior chamber angle anatomy, and inflammatory status is essential before administering Dapiprazole.

Who Should Not Take Dapiprazole?

Dapiprazole is contraindicated in patients with severe hypersensitivity to Dapiprazole, phenylpiperazines, or formulation excipients.

It is strictly contraindicated in conditions where pupillary miosis is clinically undesirable, such as acute anterior uveitis or iritis, where pupil constriction exacerbates intraocular inflammation.

Dapiprazole: Pregnancy & Fertility

Animal reproduction studies evaluating Dapiprazole demonstrate no direct teratogenicity or fetal harm at clinical doses. Dapiprazole should be administered during pregnancy only when potential clinical benefits clearly justify potential fetal risks.

It is unknown whether topical ophthalmic Dapiprazole is excreted in human breast milk. Caution is advised when administering to nursing mothers. Fertility studies demonstrate no documented reproductive impairment.

Tell Your Doctor Before Taking Dapiprazole

Tell your physician if you have a history of intraocular inflammation, iritis, or anterior uveitis. Disclose narrow-angle glaucoma, shallow anterior chamber depth, or history of intraoperative floppy iris syndrome.

Inform your doctor if you wear contact lenses or use other eye drops. Disclose concurrent medications, particularly systemic alpha-blockers, antihypertensive agents, and topical eye drops.

Dapiprazole: Dosage & Administration

Proper administration and dosage depend on immediate post-examination needs and proper reconstitution of the ophthalmic kit.

Standard Dapiprazole Dosing

For adult and pediatric patients, standard dosing is 2 drops of Dapiprazole 0.5 percent solution into the dilated eye, followed by 2 additional drops 5 minutes later.

Instillation occurs immediately after the diagnostic exam. Standard treatment consists of a 4-drop sequence per dilated eye.

How Dapiprazole Is Administered

Dapiprazole is supplied as an ophthalmic kit containing 25 mg of powder and sterile diluent, reconstituted before use.

Pour diluent into the powder vial, attach the dropper, and shake for 1 to 2 minutes. Tilt the head back, pull down the lower eyelid, and instill drops into the conjunctival sac. Apply pressure to the inner eye corner for 1 minute.

Dapiprazole: Clinical Efficacy & Research

Clinical trials established that topical Dapiprazole accelerates pupil constriction and reduces post-examination glare by over 50 percent compared to untreated controls.

Research confirmed that Dapiprazole rapidly reverses phenylephrine-induced and tropicamide-induced mydriasis within 30 to 60 minutes without inducing ciliary spasm. Clinical studies demonstrated that Dapiprazole restores reading ability and near visual acuity significantly faster than natural recovery.

Dapiprazole: Side Effects & Safety Profile

Clinical use of Dapiprazole requires monitoring for conjunctival hyperemia, ocular irritation, and transient visual disturbances.

Common Dapiprazole Side Effects

• Localized ocular symptoms including transient conjunctival hyperemia, eye redness, and conjunctival injection.
• Ocular surface symptoms including mild burning, stinging, itching, and tearing following instillation.
• Eyelid symptoms including mild eyelid drooping, eyelid edema, and localized brow ache secondary to pupil constriction.
• Visual symptoms including transient blurred vision and decreased night vision in dim light.

Serious Dapiprazole Adverse Events

• Severe acute hypersensitivity reactions, including facial angioedema and conjunctival swelling.
• Intraoperative floppy iris syndrome during cataract surgery in patients with prior alpha-1 blocker exposure.
• Exacerbation of acute intraocular inflammation or anterior uveitis in susceptible individuals.
• Transient systemic hypotension or bradycardia from excessive nasolacrimal absorption.

Managing Dapiprazole Side Effects

If mild burning or stinging occurs upon instillation, keep eyes gently closed for 1 minute.

If severe eye pain, vision changes, persistent redness, or signs of allergy develop, discontinue Dapiprazole immediately and seek medical evaluation. Mild conjunctival redness is an expected effect of alpha-blocker vasodilation.

Dapiprazole: Interactions & What to Avoid

Dapiprazole exhibits low potential for systemic drug interactions, but concomitant topical eye drops require appropriate spacing.

Dapiprazole: Interactions

Co-administration of Dapiprazole with topical alpha-adrenergic agonists like phenylephrine results in functional physiological antagonism, reversing mydriasis.

Co-administration with systemic alpha-blockers like tamsulosin may produce additive alpha blockade, increasing the risk of intraoperative floppy iris syndrome. Separate different topical eye drop instillations by at least 5 to 10 minutes.

Dapiprazole: Food & Alcohol

Topical ophthalmic administration of Dapiprazole is not affected by food or meal times.

Alcohol consumption does not directly interact with topical Dapiprazole, but alcohol can exacerbate transient dizziness if minor systemic absorption occurs.

Dapiprazole: Missed Dose, Overdose & Storage

Proper reconstitution hygiene and adherence to post-examination schedules maintain ophthalmic solution stability.

Missed Dose of Dapiprazole

Because Dapiprazole is administered as a single treatment sequence immediately following a diagnostic eye exam, routine daily missed doses do not apply.

If a post-examination treatment is omitted, the pupil will return to baseline diameter naturally over several hours.

Dapiprazole: Overdose & Emergency

Topical ocular overdose or accidental ingestion of Dapiprazole rarely causes life-threatening toxicity due to low total drug content in reconstituted vials.

In case of accidental ocular overdose, flush the eye with sterile saline or lukewarm water. In case of accidental oral ingestion, seek medical evaluation or contact poison control.

How to Store Dapiprazole

Store unreconstituted Dapiprazole kits at room temperature between 15 degrees Celsius and 30 degrees Celsius. After reconstitution, store the solution in a refrigerator or at room temperature for up to 21 days.

Dapiprazole: Patient Management & Monitoring

Systematic ophthalmic evaluation and post-instillation clinical surveillance optimize mydriasis reversal while ensuring patient comfort.

Tests Before Starting Dapiprazole

• Pre-examination ophthalmic evaluation, including visual acuity and anterior chamber assessment.
• Slit-lamp examination to confirm absence of active iritis prior to miosis.
• Baseline intraocular pressure evaluation if clinically indicated.

Monitoring During Dapiprazole Treatment

• Observation of pupillary constriction and light reflex recovery.
• Clinical monitoring for severe conjunctival hyperemia or allergic reactions.
• Evaluation for transient blurred vision before patient discharge.

Dapiprazole: Do’s and Don’ts

• Do shake the reconstituted vial thoroughly before instilling drops into the eye.
• Do apply gentle pressure to the inner eye corner for 1 minute after instilling drops.
• Don’t touch the dropper tip to your eye, fingers, or any surface to maintain sterility.
• Don’t drive at night if you experience reduced visual acuity or dim vision after pupil constriction.

Frequently Asked Questions

References

• Official FDA Prescribing Information and NDA Approval History: Rev-Eyes (Dapiprazole Hydrochloride Ophthalmic Solution), Application No. NDA 019902.
• DrugBank Online: Dapiprazole (DB00298) Profile and Pharmacological Data.
• National Center for Biotechnology Information PubChem Compound Summary: Dapiprazole.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or clinic before starting or stopping any medication.